Acrivon Therapeutics, Inc. reported a net loss of $21.0 million for the second quarter of 2025, compared to a loss of $18.8 million in the same period of the previous year. For the first half of 2025, the company recorded a net loss of $40.7 million, up from $35.3 million in the first half of 2024. The increase in losses is attributed to rising research and development expenses, which totaled $16.2 million for the second quarter, reflecting a $1.2 million increase year-over-year. The company has not generated any revenue to date and continues to anticipate significant operating losses as it advances its clinical programs.
Total operating expenses for the second quarter of 2025 were $22.6 million, a slight increase from $21.4 million in the prior year. Research and development expenses rose primarily due to increased costs associated with ACR-2316, a novel clinical-stage asset that began its Phase 1 trial in 2024. General and administrative expenses remained relatively stable, totaling $6.5 million for the quarter. The company’s accumulated deficit reached $237.7 million as of June 30, 2025, compared to $197.0 million at the end of 2024.
Acrivon continues to focus on its oncology pipeline, particularly ACR-368, which is in a Phase 2 trial for endometrial cancer. The company has received Fast Track designation from the FDA for ACR-368 and has reported promising clinical data, including a 35% confirmed overall response rate in patients with recurrent endometrial cancer. Additionally, ACR-2316 is being evaluated for its safety and tolerability in a Phase 1 trial, with initial clinical activity observed in several solid tumor types.
As of June 30, 2025, Acrivon had cash, cash equivalents, and investments totaling $147.6 million, which the company believes will fund its operations into the second quarter of 2027. However, Acrivon anticipates needing additional funding to support its ongoing clinical trials and operational activities. The company has filed a registration statement for an at-the-market offering of up to $100 million in common stock, although no sales had been made under this program as of the reporting date. Acrivon remains committed to advancing its drug candidates while navigating the challenges of funding and development in the competitive biotechnology landscape.
About Acrivon Therapeutics, Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.